Knockdown of Vascular Endothelial Cell Growth Factor Expression Sensitizes U251 Glioma Cells to Liposomal Paclitaxel and Radiation Treatment in Vitro

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2012 Sep 13

PMID 22969865

Citations 1

Authors

Yang Yu

Jianguo Feng

Xiangyun Zong

Hongjian Yang

Dehong Zou

Xiangming He

Affiliations

Soon will be listed here.

Abstract

Glioblastoma is the most aggressive malignancy of the human brain, accounting for 40% of all primary malignant brain tumors. However, there is no effective treatment for this disease. This study was designed to develop anti-vascular endothelial growth factor (VEGF) as a novel adjuvant therapy for glioblastoma. A VEGF shRNA vector was constructed to silence VEGF expression in U251 glioma cells and these cells were treated with various concentrations of liposomal paclitaxel, 6 Gy radiation or liposomal paclitaxel plus radiation. The data demonstrated that the VEGF shRNA vector significantly knocked down VEGF expression, which synergistically sensitized U251 glioma cells to liposomal paclitaxel, radiation or liposomal paclitaxel plus radiation treatment in terms of cell viability, apoptosis, colony formation and morphological changes. Future studies are required to evaluate these effects in vivo.

Citing Articles

Regulation of IL-8 gene expression in gliomas by microRNA miR-93.

Fabbri E, Brognara E, Montagner G, Ghimenton C, Eccher A, Cantu C BMC Cancer. 2015; 15:661.

PMID: 26449498 PMC: 4598972. DOI: 10.1186/s12885-015-1659-1.

References

Fountzilas G, Karkavelas G, Kalogera-Fountzila A, Karina M, Ignatiadis M, Koukoulis G . Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res. 2007; 26(6C):4675-86. View

Noble C, Kirpotin D, Hayes M, Mamot C, Hong K, Park J . Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets. 2004; 8(4):335-53. DOI: 10.1517/14728222.8.4.335. View

Harrington K, Mohammadtaghi S, Uster P, Glass D, Peters A, Vile R . Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001; 7(2):243-54. View

Aoki H, Kakinuma K, Morita K, Kato M, Uzuka T, Igor G . Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model. Int J Hyperthermia. 2004; 20(6):595-605. DOI: 10.1080/02656730410001703186. View

Winkler F, Kozin S, Tong R, Chae S, Booth M, Garkavtsev I . Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6(6):553-63. DOI: 10.1016/j.ccr.2004.10.011. View

Said H, Hagemann C, Staab A, Stojic J, Kuhnel S, Vince G . Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007; 83(3):398-405. DOI: 10.1016/j.radonc.2007.05.003. View

Kamoun W, Ley C, Farrar C, Duyverman A, Lahdenranta J, Lacorre D . Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009; 27(15):2542-52. PMC: 2739611. DOI: 10.1200/JCO.2008.19.9356. View

Furnari F, Fenton T, Bachoo R, Mukasa A, Stommel J, Stegh A . Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21(21):2683-710. DOI: 10.1101/gad.1596707. View

Meyer M . Malignant gliomas in adults. N Engl J Med. 2008; 359(17):1850. DOI: 10.1056/NEJMc086380. View

10.

Wachsberger P, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J . VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys. 2007; 67(5):1526-37. DOI: 10.1016/j.ijrobp.2006.11.011. View

11.

Jain R, Tomaso E, Duda D, Loeffler J, Sorensen A, Batchelor T . Angiogenesis in brain tumours. Nat Rev Neurosci. 2007; 8(8):610-22. DOI: 10.1038/nrn2175. View

12.

Kesari S, Schiff D, Henson J, Muzikansky A, Gigas D, Doherty L . Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008; 10(3):300-8. PMC: 2563052. DOI: 10.1215/15228517-2008-005. View

13.

Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G . Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res. 2005; 11(15):5639-44. DOI: 10.1158/1078-0432.CCR-05-0174. View

14.

Mamot C, Nguyen J, Pourdehnad M, Hadaczek P, Saito R, Bringas J . Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol. 2004; 68(1):1-9. DOI: 10.1023/b:neon.0000024743.56415.4b. View

15.

Lo H . EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol. 2009; 3(1):37-52. PMC: 3606625. DOI: 10.2174/1874467211003010037. View

16.

Behin A, Hoang-Xuan K, Carpentier A, Delattre J . Primary brain tumours in adults. Lancet. 2003; 361(9354):323-31. DOI: 10.1016/S0140-6736(03)12328-8. View

17.

Machein M, de Miguel L . Angiogenesis in gliomas. Recent Results Cancer Res. 2009; 171:193-215. DOI: 10.1007/978-3-540-31206-2_12. View

18.

Hovinga K, Stalpers L, Van Bree C, Donker M, Verhoeff J, Rodermond H . Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines--a clue to radioresistance?. J Neurooncol. 2005; 74(2):99-103. DOI: 10.1007/s11060-004-4204-7. View

19.

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

20.

Lin M, Sessa W . Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell. 2004; 6(6):529-31. DOI: 10.1016/j.ccr.2004.12.003. View